Merck & Co. (MRK) : Kahn Brothers Group Inc De reduced its stake in Merck & Co. by 2.52% during the most recent quarter end. The investment management company now holds a total of 985,419 shares of Merck & Co. which is valued at $53,094,376 after selling 25,508 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 9, 2016.Merck & Co. makes up approximately 10.20% of Kahn Brothers Group Inc De’s portfolio.
Other Hedge Funds, Including , Bank Pictet Cie (asia) Ltd reduced its stake in MRK by selling 100 shares or 0.27% in the most recent quarter. The Hedge Fund company now holds 37,412 shares of MRK which is valued at $2,015,759. Merck & Co. makes up approx 1.22% of Bank Pictet Cie (asia) Ltd’s portfolio.Welch Group reduced its stake in MRK by selling 187 shares or 1.03% in the most recent quarter. The Hedge Fund company now holds 17,934 shares of MRK which is valued at $961,262. Merck & Co. makes up approx 0.16% of Welch Group’s portfolio.Robshaw Julian Associates Inc boosted its stake in MRK in the latest quarter, The investment management firm added 2,000 additional shares and now holds a total of 77,085 shares of Merck & Co. which is valued at $4,131,756. Merck & Co. makes up approx 3.08% of Robshaw Julian Associates Inc’s portfolio.Nippon Life Insurance Co reduced its stake in MRK by selling 3,194 shares or 0.47% in the most recent quarter. The Hedge Fund company now holds 681,567 shares of MRK which is valued at $36,531,991. Merck & Co. makes up approx 0.88% of Nippon Life Insurance Co’s portfolio.John G Ullman Associates Inc boosted its stake in MRK in the latest quarter, The investment management firm added 2,840 additional shares and now holds a total of 225,672 shares of Merck & Co. which is valued at $12,375,852. Merck & Co. makes up approx 2.86% of John G Ullman Associates Inc’s portfolio.
Merck & Co. closed down -0.24 points or -0.44% at $53.88 with 71,25,157 shares getting traded on Friday. Post opening the session at $54.1, the shares hit an intraday low of $53.83 and an intraday high of $54.51 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.